Eric Dillon’s Medical Journey
Eric Dillon experienced shoulder pain and assumed it was due to a strained rotator cuff. An orthopedist initially agreed, and physical therapy seemed to alleviate the pain. However, after two years of sporadic discomfort, the pain became severe during yard work at his home in Houston in May 2024.
Returning to the orthopedist, an MRI yielded concerning results. Dillon, unfamiliar with what followed, was referred to an oncologist. He recalled, “I walked in, and she said, ‘You know why you’re here? I have a referral from another doctor to see you.’ She explained she was an orthopedic oncologist dealing with cancer.” Dillon was diagnosed with multiple myeloma, a type of blood cancer. His wife promptly arranged an appointment at MD Anderson Cancer Center, where new tests confirmed the diagnosis, outlining a treatment plan.
Dillon was unaware that his pain signaled the onset of cancer.
Understanding Multiple Myeloma
Dr. Hearn Cho, an oncologist and chief medical officer of the Multiple Myeloma Research Foundation, explained multiple myeloma. Although Cho didn’t treat Dillon, he noted the cancer affects plasma cells, impairing blood formation and potentially causing anemia, kidney damage, and high calcium levels. Damage to bones also causes pain, as with Dillon’s shoulder.
Mistaking multiple myeloma for an injury is common, Cho said. The spinal column bones frequently involved in multiple myeloma lead to back pain, yet back pain is a prevalent complaint, often attributed to musculoskeletal issues or arthritis. Diagnosing the disease can be challenging and time-consuming.
Dillon recognized the disease, as both a college friend and cousin had been diagnosed. He soon learned Black Americans are more affected by multiple myeloma; though comprising about 4% of the U.S. population, Black patients account for roughly 20% of those with the condition. They often develop the disease earlier.
Treatment and Clinical Trials
Eager to commence treatment, Dillon explained how having a plan reassured him. Shortly after beginning therapy, he joined a clinical trial, emphasizing, “Being in a clinical trial was a plus. It provided control and understanding.” Cho mentioned Black patients are often underrepresented in clinical trials, including those for multiple myeloma.
Dillon underwent eight treatment cycles over almost a year, restructuring his work schedule to accommodate the trial as an engineering consultant. He chronicled the process in a journal, noting minor side effects led to dosage adjustments. Delighted to have influenced the trial, Dillon said, “From that point forward, everything went smoothly. No major side effects or impacts.” Although some cancer remained in his shoulder bone post-trial, it was eradicated through additional radiation treatment, and his pain disappeared.
Dillon shared his relief, stating, “It was just tremendous to be pain-free and moving forward. Now, everything is beautiful.”
Looking Ahead
Currently in remission, Dillon keeps regular oncologist appointments to monitor any cancer recurrence and takes daily medication. He might undergo stem cell replacement in the future, though he hesitates due to the lengthy isolation period. Instead, Dillon cherishes time with family, celebrating his new grandchild.
Dedicated to raising awareness of multiple myeloma’s symptoms and diagnosis tools, Dillon collaborates with the Multiple Myeloma Research Foundation and urges his similarly diagnosed friend to join efforts. He strives to inform others about clinical trials and research options, saying, “This isn’t a cancer without treatment. The future is bright. The opportunities are bright.”
Edited by Nicole Brown Chau